Abstract:Importance: While the incidence of early-onset metastatic colorectal cancer (mCRC) has been increasing, studies on the age-related disparity in this group of patients are limited. Objective: To evaluate the association of age with treatment-related adverse events and survival in patients with mCRC and explore the potential underlying factors. Design, setting, and participants: This cohort study included 1959 individuals. Individual data on 1223 patients with mCRC who received first-line fluorouracil and oxaliplatin therapy in 3 clinical trials, and clinical and genomic data of 736 patients with mCRC from Moffitt Cancer Center were used to assess genomic alterations and serve as an external validation cohort. All statistical analyses were conducted from October 1, 2021, through November 12, 2022. Exposures: Metastatic colorectal cancer. Main outcomes and measures: Survival outcomes and treatment-related adverse events were compared among patients in 3 age groups: younger than 50 (early onset), 50 to 65, and older than 65 years. Results: In the total population of 1959 individuals, 1145 (58.4%) were men. Among 1223 patients from previous clinical trials, 179 (14.6%) in the younger than 50 years group, 582 (47.6%) in the 50 to 65 years group, and 462 (37.8%) in the older than 65 years group had similar baseline characteristics except for sex and race. The younger than 50 years group had significantly shorter progression-free survival (PFS) (hazard ratio [HR], 1.46; 95% CI, 1.22-1.76; P < .001) and overall survival (OS) (HR, 1.48; 95% CI, 1.19-1.84; P < .001) compared with the 50 to 65 years group after adjustment for sex, race, and performance status. Significantly shorter OS in the younger than 50 years group was confirmed in the Moffitt cohort. The younger than 50 years group had a significantly higher incidence of nausea and vomiting (69.3% vs 57.6% [50-65 years] vs 60.4% [>65 years]; P = .02), severe abdominal pain (8.4% vs 3.4% vs 3.5%; P = .02), severe anemia (6.1% vs 1.0% vs 1.5%; P < .001), and severe rash (2.8% vs 1.2% vs 0.4% P = .047). The younger than 50 years group also had earlier onset of nausea and vomiting (1.0 vs 2.1 vs 2.6 weeks; P = .01), mucositis (3.6 vs 5.1 vs 5.7 weeks; P = .05), and neutropenia (8.0 vs 9.4 vs 8.4 weeks; P = .04), and shorter duration of mucositis (0.6 vs 0.9 vs 1.0 weeks; P = .006). In the younger than 50 years group, severe abdominal pain and severe liver toxic effects were associated with shorter survival. The Moffitt genomic data showed that the younger than 50 years group had a higher prevalence of CTNNB1 mutation (6.6% vs 3.1% vs 2.3%; P = .047), ERBB2 amplification (5.1% vs 0.6% vs 2.3%; P = .005), and CREBBP mutation (3.1% vs 0.9% vs 0.5%; P = .05), but lower prevalence of BRAF mutation (7.7% vs 8.5% vs 16.7%; P = .002). Conclusions and relevance: In this cohort study of 1959 patients, those with early-onset mCRC showed worse survival outcomes and unique adverse event patterns, which could be partially attributed to distinct genomic profiles. These findings may inform individualized management approaches in patients with early-onset mCRC.

Clinical Outcome of Advanced and Metastatic Renal Cell Carcinoma Treated with Targeted Therapy: is There a Difference Between Young and Old Patients?

Disparities of Age-Based Cancer-Specific Survival Improvement with Various Clinicopathologic Characteristics for Kidney Cancer

Percutaneous Microwave Ablation under Ultrasound Guidance for Renal Cell Carcinomas at Clinical Staging T1: A Comparative Study of Clinical Results for Patients Aged Between Less Than 65 Years and 65 Years and Older.

Clinical Features and Prognostic Factors of Patients with Metastatic Renal Cell Carcinoma Stratified by Age

Targeted gene sequencing reveals disparate genomic mutations between young and older adults in renal cell carcinoma

Correlation Study Between Advanced Age and Inferior Prognosis in Stage Ⅱ Colorectal Cancer Patients

Real-world practice patterns, treatment-related toxicity, and survival outcomes in older patients with metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).

Prognostic Significance of Advanced Age in Patients with T1a Renal Cell Carcinoma Treated by Microwave Ablation: A 16-Year Experience

[A Retrospective Analysis: Comparison of the Clinical Characteristics and Prognosis in Elderly and Young Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer.].

Influence of Age and Comorbidity on Survival of Patients with Advanced Non-Small-cell Lung Cancer

Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer

Influence of age and comorbidity on treatment strategies and survival time of elderly patients with advanced non-small cell lung cancer

Analysis of the Characteristics and Prognosis of Advanced Non-Small-Cell Lung Cancer in Older Patients

Comparison of Survival Between Adolescent and Young Adult Vs Older Patients with Hepatocellular Carcinoma.

Clinicopathologic Features, Genomic Profiles and Outcomes of Younger Vs. Older Chinese Hormone Receptor-Positive (Hr+)/her2-Negative (HER2-) Metastatic Breast Cancer Patients.

Overall survival benefits of advances in NSCLC systemic treatments: Younger versus older adults.

Comparison of Clinical Features and Treatment Outcome of Breast Cancers in Young and Elderly Chinese Patients.

Dose Age Affect the Efficacy of Molecular Targeted Agents in the Treatment of Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis

Prognostic Significance of Young Age and Non-Bone Metastasis at Diagnosis in Patients with Metastatic Prostate Cancer: a SEER Population-Based Data Analysis

Are more aggressive treatments associated with better prognosis among patients with young-onset rectal cancer?

Prognostic Factors for Overall Survival with Targeted Therapy in Chinese Patients with Metastatic Renal Cell Carcinoma.